First-line Rybrevant plus Lazcluze improved survival versus the current standard of care in patients with mutated advanced or ...

CureVac recently released new clinical data. Why should investors care? Click here to find out why I am bullish on CVAC stock ...

CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of ...

The Food and Drug Administration has approved Unloxcyt (cosibelimab-ipdl) for advanced cutaneous squamous cell carcinoma.

Vir Biotechnology shares were up 67% to $13.15 after the company reported encouraging initial Phase 1 data for its dual-masked T-cell engagers, VIR-5818 and VIR-5500. The clinical-stage ...

Vir Biotechnology announced promising results Wednesday for a pair of cancer treatments, and Vir stock catapulted by double ...

Janux Therapeutics has a robust balance sheet, with $658.1 million in liquid assets and no debt. See why I reiterate my buy ...

The FDA granted priority review to a new drug application for sunvozertinib as an oral treatment for certain patients with ...